- Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
- Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
- Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
- Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
- Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
- Evaxion Announces Business Update and First Quarter 2024 Financial Results
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
- Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen
- Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré
More ▼
Key statistics
As of last trade, Evaxion Biotech A/S (EVAX:NAQ) traded at 2.91, 28.76% above the 52 week low of 2.26 set on Jun 17, 2024.
52-week range
Open | 3.09 |
---|---|
High | 3.18 |
Low | 2.77 |
Bid | 2.87 |
Offer | 2.94 |
Previous close | 3.15 |
Average volume | 24.68k |
---|---|
Shares outstanding | 521.51k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 16.42m USD |
EPS (TTM) | -56.83 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 17:24 BST.
More ▼